MBNL1 and MBNL2 transcripts in cells treated with antagomiR-218 increased in a dose-dependent manner at both time points and reached approximately 50% higher levels than in scramble control-treated DM1 cells (Fig. 3c, d). The gene discussed is MBNL1; the disease is myotonic dystrophy type 1.